GxP-compliant biodistribution and shedding studies are a required component for the clinical translation of lentiviral vector (LVV) based CAR-T cell therapies. This overview details the design and execution of these IND-enabling safety studies. We focus on quantitative PCR (qPCR) and droplet digital PCR (ddPCR) methodologies for determining vector copy number (VCN) in target tissues, non-target tissue biodistribution, and potential shedding in excreta to de-risk movement into the clinic.
What is the regulatory expectation for the duration of a lentiviral vector biodistribution study?
For integrating vectors like lentivirus, regulatory agencies typically expect monitoring to continue until vector DNA is undetectable or has reached a stable plateau in tissues. This often extends to at least 3-6 months post-administration, with some protocols requiring longer-term analysis depending on preliminary findings and the specific therapeutic construct.
Which tissues are mandatory for collection in a CAR-T biodistribution study?
A standard tissue panel includes the site of administration, gonads (testes, ovaries), hematopoietic tissues (bone marrow, spleen), major organs (brain, heart, lung, liver, kidney), and tissues with high cell turnover. For CAR-T programs, lymphoid tissues and potential sites of on-target, off-tumor activity are also included based on the target antigen expression profile.
How does qPCR sensitivity impact the interpretation of shedding study results?
The limit of detection (LOD) and limit of quantification (LOQ) of the qPCR assay are fundamental. An assay must be sensitive enough to detect clinically insignificant levels of vector shedding to establish a confident safety margin. Failure to validate a sufficiently sensitive assay can lead to regulatory requests for additional data, delaying program timelines.
Can biodistribution and toxicology endpoints be combined in a single GxP study?
Yes, it is standard practice to integrate biodistribution assessments into the main GxP toxicology study. This approach satisfies the principles of the 3Rs by minimizing animal use. It requires careful protocol design to ensure that tissue collection for VCN analysis does not interfere with standard toxicology endpoints like clinical observations and Histology.
